Ragoo Raghunathan
Vice President, Global Commercial VivoSim Labs, Inc.
Ragoo Raghunathan, PhD, is Vice President of Global Commercial at VivoSim Labs, where he works with discovery, toxicology and translational teams across pharma and biotech to apply the company’s NAMkind™ human 3D liver and intestinal models to safety and efficacy questions. VivoSim is the successor to Organovo, the 3D bioprinting pioneer whose human tissue platform produced FXR314, the IBD candidate acquired by Eli Lilly in 2025 — the same platform now offered as a service for drug efficacy and safety focused of liver and GI. Ragoo has spent his career at the interface of 3D cell culture and drug discovery, and is a long-standing advocate for human-relevant models as an alternative to animal testing, an emphasis reinforced by the FDA’s 2025 roadmap. He is also an active angel investor and mentor to early-stage life science founders. He trained at Yale University.
Seminars
- Contextualizing the liver and GI translational gap for ADCs and where human 3D models fit into hit-to-lead screening, candidate nomination, and on-demand investigative toxicology
- Establishing a reference benchmark from small-molecule datasets so ADC results are read against a clinically anchored reference set
- Investigating case studies deconstructing ADC toxicity to its components in human tissue, with side-by-side data showcasing findings that a single gut model would miss
